VUS: Definition, Uses, and Clinical Overview

VUS Introduction (What it is)

VUS means Variant of Uncertain Significance.
It is a genetic test result showing a DNA change that scientists cannot currently label as harmful or harmless.
VUS is most commonly discussed in hereditary cancer testing (germline testing) and tumor genetic testing (somatic testing).
It helps describe uncertainty in genomics rather than confirming or ruling out cancer by itself.

Why VUS used (Purpose / benefits)

VUS is used because genetic testing often finds DNA differences, and not all of them have clear medical meaning. Modern sequencing can detect many variants across many genes, but only some variants have strong evidence linking them to cancer risk, tumor behavior, or treatment response.

In cancer care, the overall purpose of reporting a VUS is to:

• Be transparent about the limits of current evidence. A VUS signals “we found a change, but we do not yet know what it means clinically.”
• Prevent over-interpretation. Labeling uncertain findings clearly helps reduce inappropriate changes to treatment or surveillance based on incomplete data.
• Support future learning and re-evaluation. As research grows and more patients are tested, some VUS may later be reclassified as benign/likely benign or pathogenic/likely pathogenic.
• Provide a complete genetic record. Documenting the variant can be helpful for later review, especially if a patient’s personal or family history changes, or if laboratory classifications are updated.

In short, VUS is a structured way to handle uncertainty in genetics while keeping cancer evaluation and treatment aligned with the strongest available evidence.

Indications (When oncology clinicians use it)

Oncology clinicians encounter and discuss VUS most often in these scenarios:

• Hereditary cancer risk evaluation, such as multi-gene panel testing for patients with a personal or family history suggesting inherited risk
• Tumor genomic profiling to look for actionable biomarkers, resistance mechanisms, or eligibility for specific therapies
• Young-onset cancers where inherited factors may be considered more often (varies by cancer type)
• Multiple primary cancers in one person or a pattern of cancers in close relatives
• Rare tumors or unusual pathology findings where genomic data may add context
• Treatment planning discussions, when a report lists pathogenic variants, benign variants, and a VUS together
• Clinical trial screening, where genomic criteria may be reviewed (a VUS may be listed but not qualify as an actionable alteration)

Contraindications / when it’s NOT ideal

Because VUS is an uncertain finding rather than a confirmed biomarker, it is generally not ideal to use it as the main basis for major clinical decisions. Situations where relying on a VUS may be unsuitable include:

• Choosing risk-reducing surgery solely because of a VUS, when no pathogenic variant is identified and other evidence is limited
• Changing systemic therapy based only on a VUS, when the variant is not validated as predictive or prognostic for that cancer type
• Testing unaffected relatives specifically for a VUS as if it were a confirmed familial mutation (often not informative; practices vary by clinician and case)
• Using a VUS as proof of hereditary cancer syndrome, when personal/family history and established criteria do not support that diagnosis
• Overriding established staging or pathology findings based on a VUS in tumor testing
• Interpreting VUS without genetics support, particularly when the result could be misunderstood or cause unnecessary distress

When genetic information is needed for decision-making, clinicians often prioritize pathogenic/likely pathogenic variants, validated biomarkers, tumor pathology, imaging, and clinical context. The most appropriate approach varies by cancer type and stage, and by the reason testing was ordered.

How it works (Mechanism / physiology)

VUS does not have a biological “mechanism of action” like a drug or radiation therapy. Instead, it is a classification category used in clinical genetics to describe the strength of evidence about a DNA variant.

At a high level, the clinical pathway works like this:

• A genetic test detects a variant. Sequencing identifies a difference from a reference DNA sequence in a gene.
• The laboratory evaluates evidence. Evidence can include population frequency data, computational predictions, functional studies (when available), how the variant segregates in families, and published clinical reports.
• A classification is assigned. Common categories include benign, likely benign, VUS, likely pathogenic, and pathogenic. A VUS sits in the middle when evidence is conflicting or incomplete.

Relevant biology depends on the gene and context:

• In germline testing, variants may be in genes involved in DNA repair, cell-cycle control, or other pathways that can influence inherited cancer risk.
• In somatic (tumor) testing, variants may affect tumor growth pathways, but a VUS means the clinical meaning is unclear for that variant in that setting.

Onset/duration/reversibility does not apply in the usual therapeutic sense. The closest relevant concept is reclassification over time: as evidence accumulates, a VUS may later be updated to a more definitive classification. The timeline and likelihood of reclassification vary by gene, variant type, lab policies, and the pace of new evidence.

VUS Procedure overview (How it’s applied)

VUS is not a procedure itself. It is a possible result from genetic or genomic testing. A general workflow in oncology settings often looks like this:

1. Evaluation/exam
   A clinician reviews the patient’s cancer diagnosis, pathology, treatments, and personal and family history. The clinical question is clarified (risk assessment, therapy selection, trial eligibility, or prognosis support).

2. Imaging/biopsy/labs (as applicable)
   For tumor testing, the lab needs tumor tissue (biopsy or surgical specimen) or sometimes blood-based circulating tumor DNA. For germline testing, a blood or saliva sample is commonly used.

3. Staging (when relevant)
   Cancer staging is determined using standard clinical tools. Genetic results generally complement—rather than replace—staging and pathology.

4. Treatment planning
   The care team reviews the full report: confirmed pathogenic findings, negative findings, and any VUS. The patient’s goals, comorbidities, and current standard-of-care options are considered.

5. Intervention/therapy
   If there are actionable findings, treatment may be guided by established biomarkers and guidelines. If the report contains only a VUS, management typically relies on other validated clinical information.

6. Response assessment
   Treatment response is monitored using standard follow-up methods (symptoms, exams, labs, imaging, and tumor markers when appropriate). A VUS usually does not change response monitoring by itself.

7. Follow-up/survivorship
   Patients may be advised to keep genetic results available for future reference. In some systems, reclassification updates may be issued by the lab or revisited during follow-up, particularly if family history evolves or new evidence emerges.

Types / variations

VUS can appear in several clinical contexts, and understanding the “type” helps interpret what the uncertainty means.

• Germline VUS (inherited testing)
  Found in DNA from blood or saliva. It may be present in all cells and can be relevant to inherited cancer risk assessment, but the risk implication is unknown until clarified.

• Somatic VUS (tumor testing)
  Found in tumor DNA. It may reflect tumor evolution, but it is not clearly linked to prognosis or treatment response without stronger evidence.

• Single-gene testing vs multi-gene panels
  Broader panels often find more variants, which can increase the chance of identifying a VUS. The tradeoff is broader coverage of possible genes of interest.

• Screening vs diagnostic use of genomics
  In hereditary cancer care, testing may be used to evaluate risk in someone with a cancer diagnosis (diagnostic in a broad sense) or to clarify risk in relatives (more screening-oriented). The role of VUS differs across these scenarios.

• Adult vs pediatric settings
  Pediatric oncology may use germline and tumor testing for distinct reasons (including rare tumor biology). Interpretation frameworks are similar, but the clinical context and implications can differ.

• Solid-tumor vs hematologic malignancies
  Tumor profiling and inherited predisposition assessment are used across both areas, but the genes tested and how results are applied vary by disease type.

• Inpatient vs outpatient workflows
  Testing can be ordered during hospitalization (e.g., newly diagnosed aggressive disease) or outpatient visits (e.g., hereditary risk consultation). The appearance of VUS depends more on the test content than the setting.

Pros and cons

Pros:

• Clarifies that a genetic change was found but is not yet clinically interpretable
• Reduces the chance of treating an uncertain variant as definitively harmful or harmless
• Preserves information that may become meaningful if reclassified later
• Encourages use of overall clinical context (pathology, stage, history) rather than a single genetic detail
• Helps standardize communication across labs and oncology teams
• Can support informed discussions with genetics professionals when uncertainty needs explanation

Cons:

• Can be confusing or stressful for patients and families
• May lead to misinterpretation if presented without clear counseling
• Typically does not provide a direct action for treatment or prevention decisions
• May complicate family discussions about inherited risk and testing
• Reclassification processes and notifications vary by laboratory and health system
• The same variant may be interpreted differently over time as evidence changes

Aftercare & longevity

With VUS, “aftercare” is less about recovery from a procedure and more about how the result is integrated into ongoing care and documentation.

Factors that can influence how VUS affects a person’s care over time include:

• Cancer type and stage, which often determine treatment intensity and follow-up needs regardless of genetic uncertainty
• Tumor biology and pathology features, which may be more clinically actionable than a VUS
• Whether the VUS is germline or somatic, because the implications for family risk and treatment context differ
• Strength and pace of emerging evidence for the gene/variant, which can affect the chance and timing of reclassification
• Quality of personal and family history documentation, since updated history can change the clinical interpretation framework
• Access to genetics services (genetic counseling, specialized clinics) for explanation, record-keeping, and coordinated follow-up
• Survivorship care and supportive services, including psychosocial support when uncertainty creates anxiety
• Comorbidities and overall health, which may guide the safest and most appropriate cancer surveillance and treatment options

In practical terms, many patients are advised to keep a copy of their genetic report and ensure it is included in their medical record so it can be revisited if new information becomes available.

Alternatives / comparisons

VUS is not an “option” in the way treatments are options, but it can be compared to other possible genetic testing outcomes and to other decision frameworks used in oncology.

• VUS vs pathogenic/likely pathogenic variant
  A pathogenic/likely pathogenic variant has evidence supporting a role in disease risk or tumor behavior and may influence management depending on context. A VUS does not have sufficient evidence to support those conclusions.

• VUS vs benign/likely benign variant
  Benign/likely benign variants are not considered disease-causing and usually do not change care. VUS remains uncertain and may warrant periodic review, but typically does not drive major decisions by itself.

• VUS vs a negative genetic test
  A negative result means no reportable pathogenic variants were found in the genes tested (limitations still apply). A VUS means a change was found, but its meaning is unclear; neither result automatically explains a cancer diagnosis.

• VUS vs observation/active surveillance decisions
  In some cancers, observation or active surveillance is guided by tumor behavior, stage, imaging, and patient factors. A VUS alone is usually not a sufficient reason to intensify or de-intensify surveillance; clinicians generally rely on validated risk factors.

• VUS in tumor testing vs established predictive biomarkers
  Some tumor biomarkers have strong evidence for selecting targeted therapy or immunotherapy in certain settings. A VUS is not the same as a validated biomarker, so it is less likely to guide treatment selection.

• Standard care vs clinical trials
  Trial eligibility may depend on specific, well-defined genomic alterations. A VUS may be recorded but often does not meet a trial’s genomic inclusion criteria unless further evidence supports its significance; this varies by trial design.

VUS Common questions (FAQ)

Q: Does a VUS mean I have cancer or will develop cancer?
A VUS does not diagnose cancer, and it does not automatically mean increased cancer risk. It indicates uncertainty about whether the variant affects disease risk or tumor behavior. Interpretation depends on the gene, personal history, family history, and other clinical findings.

Q: Can a VUS be used to choose cancer treatment?
Usually, treatment decisions rely on established clinical factors and validated biomarkers. A VUS may be noted in the record, but by itself it typically does not provide a clear treatment direction. Practices vary by clinician, cancer type, and the specific gene involved.

Q: Will a VUS ever change to a definitive result?
Sometimes a VUS is reclassified as benign/likely benign or pathogenic/likely pathogenic when more evidence becomes available. Whether and when this happens varies by the specific variant, the lab’s processes, and new research. Not all VUS are reclassified.

Q: Does genetic testing for VUS hurt or require anesthesia?
Germline testing is commonly done with a blood draw or saliva sample and does not require anesthesia. Tumor testing usually uses existing biopsy or surgery tissue; if a new biopsy is needed, discomfort and sedation needs depend on the biopsy site and method. The testing itself is performed in the laboratory.

Q: Are there side effects from getting a VUS result?
There are no physical side effects from the result itself, but uncertainty can cause emotional distress, anxiety, or confusion. Some people feel pressure to make decisions despite unclear information. Many patients find it helpful to review results with clinicians experienced in genetics communication.

Q: Should my family members be tested if I have a VUS?
Family testing strategies vary by case. Because a VUS is uncertain, testing relatives solely for that VUS is often not as informative as testing for a confirmed pathogenic variant, but there are exceptions depending on the scenario and specialist guidance. Family history and the overall clinical context matter.

Q: How long does it take to deal with a VUS result in care planning?
The discussion often happens when results return and may be revisited during follow-up. If a VUS is not clinically actionable, care planning typically proceeds based on standard clinical information. Reclassification, if it occurs, can take an unpredictable amount of time.

Q: How much does testing that can produce a VUS cost?
Costs vary widely based on the type of test (germline vs tumor), number of genes analyzed, insurance coverage, and where the test is performed. Patients may encounter separate charges for counseling, specimen processing, and interpretation. A billing team or genetics clinic can usually explain typical coverage pathways in general terms.

Q: Is a VUS result “safe” to ignore?
A VUS generally should not be treated like a confirmed harmful finding, but it also should not be erased from the record. Many clinicians treat it as neutral for decision-making unless additional evidence emerges. The safest interpretation approach is typically to integrate it with established clinical factors and revisit it if updated information becomes available.

Q: Can a VUS affect fertility or pregnancy decisions?
A VUS does not automatically indicate a known inherited cancer syndrome, so it usually does not provide clear reproductive risk information on its own. Fertility and pregnancy considerations in cancer care more often relate to planned treatments and overall health. When genetics is a concern, specialists may discuss what is known, what is unknown, and what options exist for further clarification.